FIELD: medicine.
SUBSTANCE: present invention relates to the field of medicine, namely to the use of an agent for the prevention of interstitial pneumonia, comprising oxidized dextran with M.M. from 10 to 50 kDa in the form of an aqueous solution with a concentration of 0.5-10.0 wt. %.
EFFECT: present invention provides a decrease in the severity of pathological morphological changes in the lung tissue, characteristic of interstitial pneumonia.
1 cl, 5 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS AND METHOD FOR PREVENTION OF INTERSTITIAL PNEUMONIA OF INFECTIOUS ETIOLOGY | 2021 |
|
RU2784177C1 |
| INHALED HEXAPEPTIDE FOR TREATING RESPIRATORY DISEASES ASSOCIATED WITH INTERLEUKIN-6 | 2020 |
|
RU2737799C1 |
| METHOD OF TREATING ACUTE RESPIRATORY DISTRESS SYNDROME BY DALARGIN AND A PULMONARY SURFACTANT | 2020 |
|
RU2728821C1 |
| AGENT FOR REDUCING RISK AND RELIEVING SYMPTOMS OF BETA-CORONAVIRUS INFECTION | 2021 |
|
RU2747890C1 |
| METHOD FOR TREATMENT OF LUNG DISEASES BY INHALATION ADMINISTRATION OF MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2770364C1 |
| APPLICATION OF AN ALPHA1-PROTEINASE INHIBITOR (ALPHA1-ANTITRYPSIN) FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND METHOD FOR PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME USING ALPHA1-ANTITRYPSIN | 2020 |
|
RU2757875C1 |
| STABLE AQUEOUS PHARMACEUTICAL COMPOSITION FOR INHALATIONS CONTAINING A HEXAPEPTIDE | 2020 |
|
RU2739573C1 |
| USING DALARGIN FOR PRODUCING AGENTS FOR TREATING COVID-19 CORONAVIRUS INFECTION | 2020 |
|
RU2728939C1 |
| USE OF ENISAMIUM IODIDE FOR THE PREVENTION AND/OR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | 2022 |
|
RU2799328C1 |
| BIOMEDICAL CELL PRODUCT BASED ON MAMMALIAN MESENCHYMAL STROMAL CELLS AND HEXAPEPTIDE | 2022 |
|
RU2781968C1 |
